Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of the Immunomodulation Effect of ESIT12, a Poplar-type Propolis Dry Extract and Its Efficacy in Subjects At Risk of Contracting Upper Respiratory Tract Infections (URTIs)

NCT05598749 is registered in ClinicalTrials.gov with Fytexia as lead sponsor.

NCT NCT05598749
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05598749 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of the Immunomodulation Effect of ESIT12, a Poplar-type Propolis Dry Extract and Its Efficacy in Subjects At Risk of Contracting Upper Respiratory Tract Infections (URTIs)
Lead sponsor
Fytexia
Phase
Not applicable
Overall status
Completed
Start date
December 5, 2022
Completion date
July 3, 2024
Enrollment
309 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

upper respiratory tract infection (urti)